AKR1B10 and ductal breast carcinoma in situ: There is a paucity of data on the use of either CA15.3 or CA27.29 in the diagnosis of DCIS/LCIS, and our data indicates that AKR1B10 is elevated in these premalignant conditions, being a potential marker for clinical management of the premalignant breast diseases.